The treatment of depression with paroxetine in psychiatric practice in Germany: The possibilities and current limitations of drug monitoring

Pharmacopsychiatry

Volumn 30, Issue SUPPL. 1, 1997, Pages 9-20

  Zaninelli, R ^a   Meister, W ^a  

^a SmithKline Beecham Pharma GmbH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMITRIPTYLINE; BROMAZEPAM; CARBAMAZEPINE; DOXEPIN; LITHIUM; LORAZEPAM; PAROXETINE; PROMETHAZINE; THIORIDAZINE; TRIMIPRAMINE; ZOPICLONE;

ARTICLE; DEPRESSION; DISEASE CLASSIFICATION; DRUG EFFICACY; DRUG MONITORING; DRUG SAFETY; DRUG TOLERANCE; DRUG USE; GERMANY; HUMAN; PRIORITY JOURNAL; SIDE EFFECT;

EID: 0031032483     PISSN: 01763679     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-979512     Document Type: Article

References (31)

1. American Psychiatrie Association: Diagnostic and statistical manual of mental disorders. Third Edition, Revised. Washington, DC, American Psychiatric Association, 1987
2. Bascava, L.: A double-blind study to compare the effectiveness and tolerability of paroxetine and amitriptyline in depressed patients. Acta Psychiatr. Scand. 80 (Suppl. 350) (1989) 141-142
3. Bethge, H.: Nutzen und Chancen der EDV in der Praxis des niedergelassenen Arztes. Pharm. Ind. 51 (1989) 870-873
4. Bleuler, E.: Lehrbuch der Psychiatrie. 15. Aufl., Springer, Heidelberg, New York, 1983
5. Callahan, A. M., M. Fava, J. F. Rosenbaum: Drug interactions in psychopharmacology. Psychiatr. Clin. North Am. 16 (1993) 647-671
6. Claghorn, J. L.: The safety and efficacy of paroxetine compared with placebo in a double-blind trial of depressed outpatients. J. Clin. Psychiatry 53 (Suppl.) (1992) 33-35
7. Dunbar, G. C., J. B. Cohn, L. F. Fabre, et al.: A comparison of paroxetine, imipramine, and placebo in depressed out-patients. Br. J. Psychiatry 159 (1991) 394-398
8. Fassihi, A. R., S. S. D. Robertson: Postmarketing drug surveillance - concepts, insights and applications. S. Afr. Med. J. 77 (1990) 577-580
9. Fisher, S., S. G. Bryant: Postmarketing surveillance of adverse drug reactions: patient self-monitoring. JABFP 5 (1992) 17-25
10. Griffin, J. P.: A comparison of spontaneous adverse reaction report-ing systems and more recently developed methods of postmarketing surveillance. Therapiewoche 41 (1991) 2244
11. Grohmann, R., Ch. Ströbel, E. Rüthger, P. Dirschedl, H. Helmchen, H. Hippius, B. Müller-Oerlinghausen, L. G. Schmidt, B. Wolf: Adverse psychic reactions to psychotropic drugs - a report from the AMÜP study. Pharmacopsychiat. 26 (1993) 84-93
12. Inman, W., K. Kubota, G. Pearce, L. Wilton: Prescription-event monitoring of paroxetine. PEM reports 6 (1993) 1-44
13. Jacubeit, T., D. Drisch, E. Weber: Risk factors as reflected by an intensive drug monitoring system. In: Hoigne, R., D. H. Lawson, E. Weber: Risk factors for adverse drug reations. Birkhäuser Verlag, Basel (1990) 117-125
14. Johnson, A. F.: Postmarketing surveillance: statistics and augury. J. Chron. Dis. 37 (1984) 949-952
15. Johnson, A. M.: The comparative pharmacological properties of selective serotonin re-uptake inhibitors in animals. In: Feighner, J. P., W. F. Boyer. Selective serotonin re-uptake inhibitors. John Wiley and Sons Ltd., Chichester (1991) 37-70
16. Johnson, D. A. W.: Antidepressant treatment observed: some problems of compliance by doctors and patients. In: Sims, A., O. Otto/son (eds.), Antidepressants: progress in problem areas. Franklin Scientific Projects, London, 1984
17. Johnson, D. A. W.: Non-compliance with antidepressant therapy - an underestimated problem. Int. Med. Sup. 11 (1986) 14-19
18. Longman, M. J. S.: Postmarketing surveillance and the examination of the long-term safety of antiulcer drugs. Bailliere's Clin. Gastroenterol. 7 (1993) 183-190
19. Leiper, J. M., D. H. Lawson: Why do doctors not report adverse drug reactions? Neth. J. Med. 28 (1985) 546-550
20. Linden, M., M. Osterheider. B. Schaaf, G. Fleckenstein, H. J. Weber: Fluoxetin in der Anwendung durch niedergelassene Nervenärzte. Münch. med. Wschr. 134 (1992) 836-840
21. Maddox, J. C., M. Levi, C. Thompson: The compliance with antidepressants in general practice. J. Psychopharmacol. 8 (1994) 48-53
22. Nickeisen T., M. Linden, M. Osterheider, B. Schaaf: Therapie von Depressionen. Fluoxetin in der Allgemeinpraxis. Z. Allg. Med. 69 (1993) 780-785
23. Regier D. A., W. E. Narrow, D. S. Rae, R. W. Manderscheid. B. Z. Locke, F. K. Goodwin: The de facto US mental and addictive disorders service system: Epidemiologie Catchment Area prospective 1-year prevalence rates of disorders and services. Arch. Gen. Psychiatry 50 (1993) 85-94
24. Schmidt, L. G., G. Schüssler, M. Linden, B. Müller-Oerlinghausen: Zur Häufigkeit und Therapierelevanz unerwünschter Wirkungen von Antidepressiva im Rahmen der ambulanten nervenärztlichen Behandlung. Fortschr. Neurol. Psychiat. 56 (1988) 111-118
25. Schou, J., M. Homma, M. Lumpkin, J. P. Sigel: International conference on harmonisation of technical requirements for registration of pharmaceutical for human use: ICH harmonised tripartite guideline for topic E2A: clinical safety data management: definitions and standards for expedited reporting. Step 4 paper, 25 October 1994
26. Shrivastava, R. K., S. H. P. Shrivastava, N. Overweg, C. L. Blumhardt: A double-blind comparison of paroxetine, imipramine, and placebo in major depression. J. Clin. Psychiatry 53 (Suppl.) (1992) 48-51
27. SmithKline Beecham, data on file
28. Spitzer, R. L., J. Endicott, E. Robins: Research diagnostic criteria: rationale and research reliability. Arch. Gen. Psychiatry 35 (1970) 773-785
29. Strom, B. L.: Overview of different logistical approaches of post-marketing surveillance. J. Rheumatol. 15 (Suppl. 17) (1988) 9-13
30. Wells, K. B., W. Katon, B. Rogers, P. Camp: Use of minor tranquilizers and antidepressant medications by depressed outpatients: results from the medical outcomes study. Am. J. Psychiatry 151 (1994) 694-700
31. Wolfersdorf, M., R. Zaninelli, W. Meister: Depressionsbehandlung mit Paroxetin in der allgemeinärztlichen Praxis. In preparation